Management of perceived devastating brain injury after hospital admission: a consensus statement from stakeholder professional organizations. by Harvey, D et al.
Management of Perceived Devastating Brain Injury after Hospital Admission  
 
A Consensus Statement from Stakeholder Professional Organisations 
 
 
 
 
Consensus Group Membership 
 
Chair  Dr. Dan Harvey, FICM JSC, Nottingham University Hospitals, Nottingham.  
 
Dr. John Butler, FICM Board (RCoEM), Manchester Royal Infirmary, Manchester.  
Dr. Jeremy Groves, ICS Council, Chesterfield Royal Hospital, Chesterfield. 
Dr. Alex Manara, FICM Advisor on Organ Donation, Southmead Hospital, North 
Bristol NHS Trust, Bristol. 
Prof. David Menon, University of Cambridge & Addenbrookes Hospital, Cambridge. 
Dr. Elfyn Thomas, NACCS Council, Derriford Hospital, Plymouth.   
Prof Mark Wilson, SBNS Council, Imperial College NHS Trust, St Mary's Major 
Trauma Centre, London, 
  
 
  
Abstract 
Patients with the most severe grades of life threatening brain injury are commonly 
characterised as having Devastating Brain Injury (DBI). For the purpose of this 
manuscript DBI is defined as "any neurological condition that is assessed at the 
time of hospital admission as an immediate threat to life or incompatible with 
good functional recovery AND where early limitation or withdrawal of therapy is 
being considered" 
 
The outcome in DBI patients is often death or survival with severe disability, with the 
consequence, that rapid withdrawal of life sustaining therapies (WLST) is commonly 
contemplated or undertaken.  However, accurate prognostication in life threatening 
brain injury is difficult, particularly at an early stage.  Controlled studies to provide 
evidence to guide decision making are limited, and there is a clear risk of a “self-
fulfilling prophecy”, where early prognostication leading to early WLST and death.   
 
There is a need to develop clear professional guidance in this area.  The Joint 
Professional Standards committee of the Faculty of Intensive Care Medicine and the 
Intensive Care Society convened a consensus group with representation from 
stakeholder professional organisations to produce this guidance. It recognised that 
the weak evidence base makes GRADE guidelines difficult to justify. We have made 
twelve practical, pragmatic recommendations we hope will help clinicians deliver 
safe, effective, equitable and justifiable care within a resource constrained NHS. 
 
In the situation where patient centred outcomes are recognised to be unacceptable, 
regardless of the extent of neurological improvement, then early transition to 
palliative care without admission to ICU would be appropriate. This consensus 
statement is intended to apply where the primary pathology is DBI, rather than to 
the situation where DBI has compounded a progressive and irreversible 
deterioration in other life threatening co-morbidities. 
  
1. Introduction 
 
It is recognised that accurate prognostication in life threatening brain injury is 
difficult, particularly at an early stage.  The eventual outcome for such patients is 
often death or survival with severe disability.  Many consider that admitting such 
patients to the Critical Care Uniti has little to offer in the absence of a therapeutic 
option, or that admission is inappropriate because it prolongs the dying process and 
is wasteful of precious resources. Therefore in these circumstances withdrawal of 
life sustaining treatments (WLST) is common practice and considered justifiable. 
 
A UK neurosciences ICU which sought to change current practice by admitting this 
patient cohort for observation, primarily to aid prognostication, has recently 
published their experience1ii. This has confirmed in a UK context what many 
intensivists, neurologists and neurosurgeons already accept; that occasionally 
patients go on to make a good recovery despite very poor early prognostic signs2. 
 
Without controlled studies the evidence to guide decision making will be weak when 
compared with other interventions in critical care. Such studies are unlikely and the  
risk of a “self-fulfilling prophecy”, with early prognostication leading to early WLST 
and death, continues to exist.  Case series and the development of appropriate 
registries can be helpful in increasing the evidence base. Evidence based guidelines 
as constructed by agreed GRADE criteria in such circumstances will often lead to 
weak recommendations. Nonetheless the Neurocritical Care Society in the United 
States has recently undertaken a systematic review and made several 
recommendations3 that have helped inform this consensus statement. The Joint 
Professional Standards Committee of Faculty of Intensive Care Medicine and the 
Intensive Care Society recognises that the weak evidence base makes the 
development of guidelines and protocols difficult to justify, but believes that 
guidance in this area would help practicing clinicians deliver safe, effective, equitable 
and justifiable care within a resource constrained NHS. The Joint Professional 
Standards committee therefore convened a consensus group with representation 
from stakeholder professional organisations to produce this guidance.  
 
This statement is intended to help consultants when making decisions on the 
management of patients admitted with a perceived devastating brain injury (DBI), 
and should not replace their clinical judgment.  
 
 
  
                                                        
i CCU or ICU throughout this document  
ii also available open access at http://journals.sagepub.com/doi/full/10.1177/1751143716670410 
2. Definition of Devastating Brain Injury  (DBI) 
 
For the purpose of this statement DBI is defined as:  
 
"Any neurological condition that is assessed at the time of hospital admission as an 
immediate threat to life or incompatible with good functional recovery AND where 
early limitation or withdrawal of therapy is being considered" 
 
This definition emphasises both the importance of an early clinical assessment of the 
mortality risk and the likely functional outcomes, as well as the proposed clinical 
course of action. It is derived from the recommendations of the Neurocritical Care 
Society3 and from UK experience in admitting such patients from the Emergency 
Department (ED) to the ICU1,4. Many patients admitted with neurological conditions 
that are an immediate threat to life or considered as incompatible with a good 
functional recovery are still treated actively and aggressively. The definition is only 
met when a treatment limitation or withdrawal decision is also being considered at 
this early stage. This definition of DBI is not dependent on the underlying diagnosis. 
It can be used in patients with any primarily neurological diagnosis, most commonly 
traumatic brain injury, subarachnoid haemorrhage, intra-cerebral haemorrhage, 
stroke and hypoxic brain injury from a range of causes. The early limitation or WLST 
is usually considered in DBI because the presenting neurological insult is not thought 
to be compatible with survival and not amenable to active intervention.  In practice 
this usually means that a short period of organ and airway support is provided in the 
emergency department followed quickly by a transition to palliative care and 
terminal extubation.  
 
Although many patients with hypoxic brain injury following the return of 
spontaneous circulation after a cardiac arrest may have met the criteria for DBI in 
the past, currently only a minority of these patients have an early treatment 
limitation decision applied since current international post resuscitation guidelines 5 
recommend the admission of such patients to ICU and delayed prognostication.  
 
In the situation where patient centred outcomes are recognised to be unacceptable, 
regardless of the extent of neurological improvement, then early transition to 
palliative care without admission to ICU would be appropriate. This consensus 
statement is intended to apply where the primary pathology is DBI, rather than to 
the situation where DBI has compounded a progressive and irreversible 
deterioration in other life threatening co-morbidities. 
  
3. Recommendations  
 
1. Patients who present with severe brain injury often require time sensitive 
interventions.  Where these are potentially meaningful in the overall 
clinical context, such interventions should be undertaken without delay.  
2. There are patients in whom severe brain injury is perceived to be 
devastating and active intervention not thought to be appropriate. 
However, prognostication at this stage can be inaccurate, and a period of 
physiological stabilisation and observation is recommended to improve the 
quality of decision making. 
3. Patients who are intubated will require admission to critical care for this 
period of observation, unless the extent of co-morbidity makes continued 
organ support of no overall benefit regardless of the extent of potential 
neurological recovery. Patients not requiring stabilisation with airway, 
ventilatory or circulatory support can be observed on a medical ward.  
4. During the period of observation the therapeutic aim is to provide 
cardiorespiratory stability in order to facilitate accurate neurological 
prognostication. If the patient's neurological function continues to 
deteriorate despite cardiorespiratory stability the multi-disciplinary team 
(MDT) may consider this to be an appropriate trigger for a decision to 
WLST. If the patient shows signs of improvement the MDT should 
reconsider the treatment limitation decision. 
5. Communication of the aims and goals of treatment should be consistent 
and made clear to the family and members of the MDT from the outset. 
Admission to ICU may raise unrealistic expectations. The patient’s family 
should be informed of the expectation of continued deterioration with 
death the most likely outcome, but that additional time will increase the 
certainty of this prognosis.  
6. The duration of the period of observation should be determined by a 
combination of clinical judgement, changes in neurological function, the 
degree of support required to maintain physiological stability, and 
communication with patient’s family to determine patient preferences.  
7. The diagnosis of brain stem death often aids communication and decision 
making at the end of life. Continuation of intensive care in order to support 
the diagnosis of BSD is appropriate in such circumstances.  
8. Organ donation should be a routine consideration in end of life care 
planning.  
9. An approach for consent to organ donation should only occur after the 
family understand and accept the diagnosis of brain death or the reasons 
for WLST, and then undertaken in collaboration with a specialist nurse for 
organ donation. 
10. The Joint Standards Committee of the FICM / ICS should engage with other 
stakeholder organisations to remove barriers to the adoption of these 
recommendations. Stakeholder organisations should work with ICNARC and 
the Society of British Neurological Surgeons to ensure data are captured on 
this cohort within critical care, the emergency department and the wider 
hospital environment. 
11. Mortality is an inappropriate performance metric in this patient cohort. 
Detailed analysis is required to assess the effect of implementation of these 
recommendations on both individual consultant and unit mortality 
statistics, and to explain possible outliers that may result. 
12. Audit and analysis of outcome data for these patients should be routinely 
collected nationally to ensure good governance.  
  
 
4. Prognostication 
 
The prognostication of outcome from neurological disease has received much 
attention.  Some variables have prognostic significance across several diagnostic 
categories.  These include age, conscious level at presentation, physiological status, 
extent of brain injury identified by imaging, and the presence and severity of co-
morbidities6,7. These have been integrated to varying extents in disease-specific 
prognostic schemes for traumatic brain injury (TBI) 8 9, aneurysmal subarachnoid 
haemorrhage 10-12, intracerebral haemorrhage13, ischaemic stroke14, and cardiac 
arrest15,16. These schemes are based on probabilistic models that relate clinical 
features and investigations at presentation to outcome, and display varying degrees 
of accuracy and precision.  While the performance of many of these schemes has 
been subject to validation in populations of patients, they all suffer from problems 
that make their application to individual patients unsatisfactory.   
First, though their performance in groups of patients may be acceptable, the 
precision of prediction is either not routinely provided, or tends to be inadequate for 
decision-making in individual patients.  For example, the CRASH prognostic model9 
often shows confidence intervals of up to + 5% when predicting mortality in TBI.  
Consequently, a predicted mortality close to 100% may have a lower CI of ~95%, 
suggesting survival of one in 20 patients. Such imprecision may be particularly 
relevant when prognostic schemes that have been developed in one context are 
applied to a different clinical environment, where they may need recalibration to 
restore even baseline levels of precision17. 
Second, many prognostic schemes tend to provide prediction of mortality, rather 
than functional outcome, a substantial failing when the quality of survival is seen as 
important by patients and their families.  Where functional outcomes are provided, 
precision tends to be either unreported, or imperfect, as for mortality. 
Third, even recently published prognostic schemes are reliant on large retrospective 
datasets, and consequently do not reflect current therapeutic possibilities.  
Accumulating data, and/or emerging advances and changed management in several 
conditions may invalidate prognostic expectations (as for the prognostic import of 
motor responses and myoclonus following cardiac arrest16), or a prognostic feature 
may undergo refinement in a way that was not appreciated when the original 
prognostic scheme was devised (as for myoclonus18).  The sensitivity of prognostic 
features may be altered by changes in therapy (for example, the common use of pre-
hospital sedation has diminished the prognostic power of the GCS19, and the 
significance of motor responses following cardiac arrest has been altered by the use 
of therapeutic hypothermia20). Further, newer therapies and more aggressive 
management may mean that current outcomes are often better than established 
prognostic schemes and past experience might suggest, even for conditions that 
might be perceived to be devastating21,22. 
Fourth, the validation of existing prognostic schemes is heavily confounded by the 
likelihood that patients with the worst expected prognosis often have less aggressive 
therapy or have therapy withdrawn 23, making prediction of mortality a self-fulfilling 
prophecy24 25.  This phenomenon can result in erroneous reinforcement of 
prognostic schemes.  Even where patients do not die, their functional outcomes may 
not be as favourable as might have been achieved by continued aggressive therapy.  
Also there is an emerging realisation that severe brain injury takes a long time to 
achieve maximal outcome, and the typical assessment of outcome at hospital 
discharge, or even at six months may underestimate the quality of survival, 
particularly in patients who have undergone extremely aggressive management 26. 
Finally, societal expectations of what is accepted as a “life worth living” are 
constantly being recalibrated, and many patients who are severely disabled express 
satisfaction with quality of life27-29.  Understanding these changing trends is 
important if clinicians and clinical services are to reflect the expectations of the 
populations we treat.   
However, notwithstanding these imperfections in prediction of outcome in 
individual patients, clinical care of patients with severe brain injury demands that 
clinicians make judgments regarding the advisability of continued active therapy in 
the face of a high risk of undesirable functional outcome7.  Consequently, we need 
to find ways to provide greater assurance of prediction of such undesirable outcome.  
The change in status with physiological stabilisation, and the initial response to 
active therapy provides one route to such greater assurance.  Most prognostic 
schemes are populated by variables that are recorded at a single time point – 
typically at admission.  Assessment of response to stabilisation and active therapy 
not only refines the precision of such prognostication, but also ensures that 
potentially retrievable patients are not mistakenly abandoned, and that the 
potential of clinical outcome in survivors is maximised7. Indeed, it is precisely this 
group of patients with the worst expected prognosis, who might have their outcome 
substantially benefitted by aggressive management and specialist care 23,30,31.  The 
period of such stabilisation and interval to reassessment will depend on the 
individual patient, but may lie between 24 and 72 hours. 
  
5. Observation & Limitations of therapy 
The purpose of an admission to ICU in the context of DBI is to provide physiological 
support whilst allowing further time for observation and monitoring, rather than the 
prolongation of an inevitable death. Observations and further investigations are 
aimed at confirming the initial prognostication and the exclusion of potential 
confounders. Treatment limitations should be agreed and communicated with 
patient’s family and ICU team at the outset. This may include limitation of additional 
organ support and interventions, for example renal replacement therapy, 
neurosurgical interventions, ICP monitoring and the application of a DNACPR 
decision. 
The key observation is simple repeated clinical monitoring of conscious level 
(Glasgow Coma Score) and pupillary reactions after physiological stability has been 
achieved and any confoundersiii  recognised and treated. This management can be 
provided in the patient’s local ICU.  The development of physiological instability and 
organ dysfunction during the period of observation is common. Mechanical 
ventilation and inotropic support are usually required and are appropriate. When a 
rapid and significant escalation in therapy is required to maintain physiological 
stability, the responsible consultant should review the relative harms and burdens of 
continued intensive care regularly.  
In patients who show an improvement in their neurology, further discussion with a 
regional neurosciences centre is recommended; repeat imaging, neurophysiological 
studies and / or patient transfer may be required.  
The use of sedative medication early in the presentation of patients with DBI is 
recommended as a part of emergency resuscitation to prevent secondary brain 
injury, for example during intubation32. After that sedatives should only be used if 
required to control seizures, allow tolerance of mechanical ventilation, and to 
manage any concerns about pain or distress. Concerns of this kind often suggest 
neurological recovery and consideration should be given to transitioning to active 
therapy. The doses used should be kept minimal to allow continued observation of 
the pupils and motor responses, and sedation holds practiced as usual. 
A proportion of patients with DBI will develop raised intracranial pressure with 
subsequent brainstem compression and secondary hypertension during the period 
of observation. This is the expected progression of many conditions presenting as 
DBI.  Short acting sedative agents may be used to manage the hypertension but 
there are advantages to the use of short acting Beta-blocking agents (e.g. esmolol) in 
this context.  It may be considered appropriate to continue and indeed escalate 
support to allow a diagnosis of brain stem death when this is a possibility. The 
diagnostic certainty of death confirms prognostication and futility, and can aid 
communication with families.     
 
  
                                                        
iii See Appendix 1. 
Co-Morbidity 
Age is recognised to significantly worsen the outcome of patients with critical illness 
and brain injury9, a relevant factor may be the incidence of comorbidity. The 
influence of comorbidity on the decision to admit a patient to ICU should be the 
same for a patient with DBI as for patients with other diagnoses. Even in the minority 
of cases that may have good neurological outcomes, there will usually be functional 
deficits. Recovery will be prolonged and may require aggressive interventions. If 
these aspects are unacceptable or inappropriate for a patient, then the additional 
prognostic certainty as to the exact neurological deficit resulting from DBI is not 
helpful in decision-making. In the situation where patient centred outcomes are 
recognised to be unacceptable, regardless of the extent of neurological 
improvement, then early transition to palliative care without admission to intensive 
care would be appropriate. This consensus statement is intended to apply where the 
primary pathology is DBI, rather than to the frequent situation where DBI has 
compounded progressive and irreversible acute or chronic deterioration in other 
organ function. 
 
Communication  
An admission to intensive care is usually for therapeutic purposes, which can 
improve the patient’s chances of achieving an outcome acceptable to them. 
Intensive care admission usually leads to hope and expectations amongst patients, 
families and the wider MDT (including their treating intensive care team). In the 
situation of admission of DBI for the purposes of prognostication such hopes and 
expectations need to be managed by honest and realistic discussions of the most 
likely outcome. Multi speciality communication is important in ensuring consistency.  
It is important that all parties understand the reasons for ICU admission, any 
limitations in applied therapies, and the likely trajectory of deterioration and 
subsequent death.  Difficult conversations may need to occur in stages, and 
communication should be tailored to the needs of patients and families. Establishing 
the patient’s values and preferences is useful in planning end of life care. Intensive 
care teams are experienced in the transition from active therapy to palliative care, 
and it may be that the emotional impact of this experience is reduced with intensive 
care admission.  
  
6. Transition to active therapy  
Improvements in neurological status should prompt rapid clinical re-evaluation and 
consideration of escalation in therapy to continue to support recovery and other 
specific measures to protect the brain. The patient should be discussed once again 
with regional neurosciences centre, as a change of focus to active management of 
intracranial pathology may necessitate further investigation and / or transfer to a 
tertiary neurocritical care facility. 
It is important that the treating MDT remains clear about the aims and goals of 
treatment at all times. If there is improvement and the patient is transitioned to 
active therapy this should be clearly documented, along with any limitations that 
remain in force, and the new treatment goals communicated to patient’s family and 
the MDT. It is essential to ensure that the family’s expectations remain realistic, 
explaining that any initial improvement may be transitory and is a trigger for 
continued observation and support, and not necessarily an indication of an improved 
prognosis.  
A clear understanding of patient wishes and preferences will influence decision 
making in such circumstances, as discussed in the next section.  
 
7. Transition of End of Life Care & Organ Donation  
A crucial intervention in the DBI pathway is delaying the decision to WLST and 
achieving physiological stability 3. The primary objective is to stabilise the patient and 
allow more time to observe the patient ensuring accurate prognostication. A minority 
of patients will show signs of neurological improvement and their treatment plan 
should be revised accordingly. The majority will however deteriorate further or even 
progress to neurological death. The increased time afforded by delaying the WLST 
will also allow secondary objectives to be met i.e. better communication, planning 
and delivering individualised end of life care and the consideration of organ donation 
when appropriate1,4 . 
End of life care planning should begin at the time of admission to the ED or ICU 
rather than at the time of making a decision to WLST. This begins with a frank and 
open discussion with the relatives including the high likelihood of death and the 
possibility of survival with disability. The interview with the relatives should also 
explore the patient’s values and preferences and incorporate these into a bespoke 
end of life care plan33. A shared decision making approach between the clinical staff 
and the family should be adopted as recommended by many international critical 
care societies34 and required by the Mental Capacity Act (Adults with Incapacity Act 
in Scotland).  This avoids both a paternalistic approach to decision making or an 
informed approach where relatives have to make difficult decisions at a stressful 
time33. All treatment plans must identify clear objectives and outcomes within a 
specific time frame and these should be agreed with the patient’s relatives 35 . The 
value of incorporating palliative care as part of the end-of-life care in ICU is 
increasingly accepted as a means of improving the quality of care36. It aims to 
prevent and relieve suffering by means of early identification, assessment and 
treatment of pain and other physical, psychosocial and spiritual problems37 38. 
Consideration of organ donation should begin when a patient continues to 
deteriorate and WLST is being considered, or alternatively when it appears likely that 
a patient will meet the criteria for confirming death using neurological criteria. Both 
scenarios should lead to an early notification and discussion with a specialist nurse in 
organ donation (SN-OD) as recommended by the National Institute for Health and 
Clinical Excellence39 and best practice guidelines40. The relatives should not be 
approached to request organ donation until they have accepted the futility of 
continued organ support and the reasons for the WLST and the consequent 
inevitability of death, or after the confirmation of death using neurological criteria. It 
is good practice to decouple the conversation about neurological testing or the WLST 
from the family approach regarding organ donation41. A planned and collaborative 
approach between the ICU team and the SN-OD team should be routine practice35. 
This not only improves the quality of the information and support provided to the 
family, but also improves consent rates42.  
 
  
8. Governance  
a. There should be an identified lead clinician for the management of DBI 
patients within each trust. This could be incorporated within existing 
clinical management roles, for example within the Emergency 
Department, Intensive Care or Neurology / Neurosurgical Services.  
b. Prospective audit of patients admitted with DBI should be undertaken 
locally and nationally.   
c. Cases from this patient cohort should be regularly reviewed in a multi-
disciplinary meeting, for example morbidity and mortality meetings.  
d. In clinical environments where the transfer of DBI patients is sometimes 
necessary, joint case review with regional centres would be ideal.   
 
 
9. Existing Relevant Guidance  
 
 Good Medical Practice. General Medical Council. 2013. 
 Treatment and care towards the end of life. Good practice in decision-
making. General Medical Council. 2010.  
 Mental Capacity Act 2005, HM Government & Adults with Incapacity 
(Scotland) Act 2000.  
 Guidelines for the Provision of Intensive Care. Faculty of Intensive Care 
Medicine and The Intensive Care Society. 2015.  
 Organ donation for transplantation: early identification of potential organ 
donors. National Institute of Health and Care Excellence. 2016.  
 Timely identification and referral of potential organ donors. National 
Health Service Blood and Transplant. 2012. 
 Approaching the families of potential organ donors. National Health 
Service Blood and Transplant. 2013.  
 A code of practice for the diagnosis and confirmation of death. Academy 
of the Royal Colleges. 2010.  
 
 
  
10. Barriers to implementation & Other Considerations.  
 
Resources 
 
a. ICU Capacity 
Even in countries with considerably higher ICU capacity than the UK the 
practical, moral and financial impacts of using increased ICU resources at 
the end of life are increasingly recognised43. The equitable and ethical 
management of scare ICU beds and resources is an everyday challenge 
for ICU consultants in the UK and a skill that is expected of this role. 
Relevant GMC guidance is useful, for example Good Medical Practice 
states “Decisions about what treatment options can be offered may be 
complicated by resource constraints – such as funding restrictions on 
certain treatments in the NHS, or lack of availability of intensive care 
beds. In such circumstances, you must provide as good a standard of care 
as you can for the patient, while balancing sometimes competing duties 
towards the wider population, funding bodies and employers”. 
 
b. ED Capacity.  
It is envisaged that admission of patients with DBI to critical care units will 
have little impact on emergency department capacity.  While there may 
be a delay while a critical care bed is obtained this is likely to be similar 
to, or less than, the time taken to manage treatment withdrawal with in 
the emergency department. 
 
c. Equipment 
Access to specialised investigations (MRI, EEG) or techniques (ICP 
monitoring) may hamper decisions on prognostication and optimal 
management of the DBI patient outside a regional centre. Early 
communication with the regional neuroscience centre is recommended.  
 
d. Communication & Referral Pathways 
The frequency with which some critical care staff will manage DBI 
patients will be low, particularly in smaller units. Confidence in decision 
making will be improved by good communication and referral pathways 
between regional neuroscience centres and secondary care hospitals. 
 
 
Quality Metrics 
 
e. ICNARC, Unit and Hospital Mortality  
The available data on outcomes for patients with DBI is limited for the 
reasons outlined in the introduction.  This lack of outcome data, and 
potentially the impact of high mortality, may hamper acceptance of the 
potential benefit of a prognostication window.  Lack of demographic, 
subgroup and length of stay information may prejudice appropriate 
resource allocation by both providers and commissioners. 
 
f. Surgical Outcomes 
There are good reasons to question the use of mortality statistics as a 
measure of the quality of surgical practice44 and the abuse of such 
statistics serves as a potential barrier, and a disincentive, to decision 
making in the patient's best interest in the setting of DBI. We recommend 
that these patients are excluded from the neurosurgical / intensive care 
unit's quality metrics which make use of standardised mortality ratios as 
an outcome measure. It may be helpful if the admitting consultant were 
to be the duty intensivist.  
 
Education  
 
g. Improved understanding of which patient subgroups may benefit from a 
prognostication window will require collection of quality data, and our 
recommendations include the capture of robust data. The existing 
evidence base and the results of future data analysis need to be 
understood by clinicians and this subject area would be an appropriate 
topic for local CPD sessions. 
 
Staff Training  
 
h. Communication Skills 
 
Managing the expectations of relatives and staff when a patient is 
admitted with limited prospect of recovery will require excellent 
communication skills. Advanced communication training can be a useful 
addition to intensive care unit educational programs45.  
 
Psychological Issues 
 
i. The multi professional staff who look after patients with limited 
prospective of recovery may need psychological support. Existing unit 
resources may be supplemented by specific support mechanisms, e.g 
Swartz rounds.  
 
 
 
  
Appendix 1 - Table of potential confounders of poor initial GCS in TBI 
 
Drugs (prescription, administered, illicit) inc. alcohol 
Seizure activity 
Spinal cord injury  
Direct cranial nerve injury 
Physiological derangement (hypotension, hypoventilation, hypoxia and 
hypercapnia)  
Ophthalmological injury / conditions 
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